Health Economic Evaluation of Non-Melanoma Skin Cancer and Actinic Keratosis

PharmacoEconomics

Volumn 22, Issue 2, 2004, Pages 83-94

  Higashi, Mitchell K ^a   Veenstra, David L ^a   Langley, Paul C ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON;

ACTINIC KERATOSIS; BASAL CELL CARCINOMA; BEAM THERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; COMORBIDITY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; COST OF ILLNESS; COST UTILITY ANALYSIS; CRYOSURGERY; DATA BASE; ECONOMIC EVALUATION; EVALUATION; FAMILY MEDICINE; HEALTH ECONOMICS; HUMAN; LITERATURE; MEDICARE; MELANOMA; OTORHINOLARYNGOLOGY; PRIORITY JOURNAL; REVIEW; SKIN CANCER; TUMOR RECURRENCE;

CLINICAL TRIALS; HEALTH CARE COSTS; HUMANS; KERATOSIS; PHOTOSENSITIVITY DISORDERS; SKIN NEOPLASMS;

EID: 1242317128     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200422020-00002     Document Type: Review

References (54)

1. Cook BE, Bartley GB. Epidemiologic characteristics and clinical course of patients with malignant eyelid tumors in an incidence cohort in Olmsted County, Minnesota. Ophthalmology 1999; 106 (4): 746-50
2. Staples M, Marks R, Giles G. Trends in the incidence of non-melanocytic skin cancer (NMSC) treated in Australia 1985-1995: are primary prevention programs starting to have an effect? Int J Cancer 1998; 78; 144-8
3. Smith ES, Feldman SR, Fleischer AB, et al. Characteristics of office-based visits for skin cancer: dermatologists have more experience than other physicians in managing malignant and premalignant skin conditions. Dermatol Surg 1998; 24 (9): 981-5
4. Fleming ID, Amonette R, Monaghan T, et al. Principles of management of basal and squamous cell carcinoma of the skin. Cancer 1995; 75: 699-704
5. Glogau RG. The risk of progression to invasive disease. J Am Acad Dermatol 2000; 42 (1 Pt 2): 23-4
6. Frost C, Williams G, Green A. High incidence and regression rates of solar keratoses in a Queensland community. J Invest Dermatol 2000; 115: 273-7
7. Greenlee RT, Hill-Harmon MB, Murray T et al. Cancer statistics, 2001. CA Cancer J Clin 2001; 51: 15-36
8. Kim ES, Kies M, Herbst RS. Novel therapeutics for head and neck cancer. Curr Opin Oncol. 2002 May; 14 (3): 334-42
9. PBAC. Pharmaceutical Benefits Advisory Committee. Guidelines for the pharmaceutical industry on preparation of submissions to the PBAC, 1999 [online]. Available from URL: http:// partners.health.gov.au/hfs/haf/docs/ pharmpac/part1.htm [Accessed 1999 Dec 20]
10. Canadian Coordinating Office for Health Technology Assessment. Guidelines for economic evaluations of pharmaceuticals. 2nd ed. Canada: CCOHTA, 1997
11. NICE. National Institute for Clinical Excellence. Appraisal of new and existing technologies: interim guidance for manufacturers and sponsors, 1999 August [online]. Available from URL: http://www.nice.org.uk/appraisals/apr_gide. htm [Accessed 1999 Dec 20]
12. Drummond M, Dubois D, Garattini L, et al. Current trends in the use of pharmacoeconomics and outcomes research in Europe. Value Health 1999; 2: 323-32
13. Langley PC. Formulary submission guidelines for Blue Cross and Blue Shield of Colorado and Nevada: structure, application and manufacturer responsibilities. Pharmacoeconomics 1999; 16: 211-24
14. Mather DB, Sullivan SD, Augenstein D, et al. Incorporating clinical outcomes and economic consequences into drug formulary decisions: a practical approach. Am J Manag Care 1999; 5: 277-85
15. Sullivan SD, Lyles A, Luce B, et al. AMCP guidance for submission of clinical and economic evaluation data to support formulary listing in US health plans and pharmacy benefits management organizations. J Managed Care Pharm 2001; 7: 272-82
16. MEDLINE. National Library of Medicine, December, 1999 [online]. Available from URL: http://www.ncbi.nlm.nih.gov/ pubmed/ [Accessed 2001 Dec 20]
17. CancerLit Bibliographic Database. National Cancer Institute, November 1999 [online]. Available from URL: http:// cnetdb.nci.nih.gov/cancerlit.html [Accessed 2001 Dec 20]
18. CDC Wonder. Center for Disease Control, November 1998 [online]. Available from URL: http://wonder.cdc.gov/ [Accessed 2001 Dec 20]
19. Combined Health Information Database. National Institutes of Health; Center for Disease Control and Prevention; Health Resources and Services Administration, December, 1999 [online]. Available from URL: http://chid.nih.gov/ [Accessed 2001 Dec 20]
20. Econlit. Bibliographic coverage of the journal articles, dissertations, books, and conference proceedings in economics, January, 1999 [online]. Available from URL: http://www.lib.washington.edu/silverplatter/webspirs/ [Accessed 2001 Dec 20]
21. EMBASE. Drugs and pharmacology, February 1999 [online]. Available from URL: http://www.lib.washington.edu/silverplatter/webspirs/ [Accessed 2001 Dec 20]
22. Evidence-Based Medicine. ACP-ASIM Online, December, 1999 [online]. Available from URL: http://www.acponline.org/journals/ebm/pastiss.htm [Accessed 2001 Dec 20]
23. Harrison's Online. The McGraw-Hill companies, March 1999 [online]. Available from URL: http://www.harrisonsonline.com/ [Accessed 2001 Dec 29]
24. HealthSTAR. Clinical and non-clinical aspects of health care delivery, including patient outcomes, health insurance, health policy, economics, and laws and regulations, January 1999 [online]. Available from URL: http://www.lib.washington.edu/silverplatter/webspirs/ [Accessed 2001 Dec 20]
25. HEED. Health Economic Evaluations Database, OHE-IFPMA Database Ltd, December, 1999. CD-ROM [Accessed 2000 Jan 11]
26. Research Library Periodicals. Bibliographic coverage of journals in all subject areas. January, 1999 [online]. Available from URL: http://proquest.umi. com/pqdweb [Accessed 2001 Dec 20]
27. UnCoverWeb. Index of English language periodicals, December, 1999 [online]. Available from URL: http:// uncweb.carl.org/ [Accessed 2001 Dec 20]
28. American Academy of Dermatology [online]. Available from URL: http://www.aad.org/ [Accessed 2001 Dec 20]
29. American Society of Dermatology [online]. Available from URL: http://www.asd.org/ [Accessed 2001 Dec 20]
30. American Society of Plastic & Reconstructive Surgery [online]. Available from URL: http://www.plasticsurgery.org/ [Accessed 2001 Dec 20]
31. Dermatology Foundation [online]. Available from URL: http:// www.dermfnd.org/ [Accessed 2001 Dec 20]
32. European Society for Dermatological Research [online]. Available from URL: http://dermatology.azn.nl/esdr/ [Accessed 2001 Dec 20]
33. Internet Dermatology Society [online]. Available from URL: http://www.telemedicine.org/ids.htm [Accessed 2001 Dec 20]
34. International Society of Cutaneous Lymphomas [online]. Available from URL: http://www-usz.unizh.ch/iscl/isclhome.htm [Accessed 2001 Dec 20]
35. NIAMS. National Institute of Arthritis and Musculoskeletal and Skin Diseases. Available from URL: http://www.niams.nih.gov/ [Accessed 2001 Dec 20]
36. AHRQ. Agency for Health Research and Quality [online]. Available from URL: http://www.ahcpr.gov/ [Accessed 2001 Dec 20]
37. Drummond MF, O'Brien B, Stoddart GL, et al. Methods for the economic evaluation of health care programmes. 2nd ed. New York: Oxford University Press, 1997: 139-99
38. Shiell A. Consideration of the cost of interferon alfa-2b in the treatment of basal cell carcinoma. Australas J Dermatol 1994; 35: 71-5
39. Welch ML, Anderson LL, Grabski WJ. Evaluation and management of nonmelanoma skin cancer: the military perspective. Dermatol Clin 1999; 17 (1): 19-28
40. Liu FF, Maki E, Warde P, et al. A management approach to incompletely excised basal cell carcinomas of skin. Int J Radiat Oncol Biol Phys 1991; 20 (3): 423-8
41. Cook J, Zitelli JA. Mohs micrographic surgery: a cost analysis. J Am Acad Dermatol 1998; 39: 698-703
42. Miller PK, Roenigk RK, Brodland DG, et al. Cutaneous micrographic surgery: Mohs procedure. Mayo Clin Proc 1992; 67 (10): 971-80
43. Housman TS, Feldman SR, Williford PM, et al. Skin cancer is among the most costly of all cancers to treat for the Medicare population. J Am Acad Dermatol 2003 Mar; 48 (3): 425-9
44. Joseph AK, Mark TL, Mueller C. The period prevalence and costs of treating nonmelanoma skin cancers in patients over 65 years of age covered by medicare. Dermatol Surg 2001 Nov 27 (11): 955-9
45. Housman TS, Williford PM, Feldman SR, et al. Nonmelanoma skin cancer: an episode of care management approach. Dermatol Surg 2003 Jul; 29 (7): 700-11
46. Stern RS. The mysteries of geographic variability in nonmelanoma skin cancer incidence. Arch Dermatol 1999; 135: 843-4
47. Chuang TY, Popescu A, Su D, et al. Basal cell carcinoma: a population-based incidence study in Rochester, Minnesota. J Am Acad Dermatol 1990; 22: 413-7
48. Marghoob A, Kopf AW, Bart RS, et al. Risk of another basal cell carcinoma developing after treatment of a basal cell carcinoma. J Am Acad Dermatol 1993; 28: 22-8
49. Thissen MR, Neumann MH, Schouten LJ. A systematic review of treatment modalities for primary basal cell carcinomas. Arch Dermatol 1999; 135; 1177-83
50. Marcil I, Stern RS. Risk of developing a subsequent nonmelanoma skin cancer in patients with a history of nonmelanoma skin cancer: a critical review of the literature and meta-analysis. Arch Dermatol 2000; 136: 1524-30
51. Marks R, Rennie G, Selwood TS. Malignant transformation of solar keratoses to squamous cell carcinoma. Lancet 1988; I (8589): 795-7
52. Harvey I, Frankel S, Marks R, et al. Non-melanoma skin cancer and solar keratoses: I. methods and descriptive results of the South Wales Skin Cancer Study. Br J Cancer 1996; 74 (8): 1302-7
53. Frost CA, Green AC. Epidemiology of solar keratoses. Br J Dermatol 1994; 131 (3): 455-64
54. Dinehart SM. The treatment of actinic keratoses. J Am Acad Dermatol 2000; 42 (1 Pt 2): 25-8